Igyxos Biotherapeutics is developing monoclonal antibodies that enhance the activity of Follicle Stimulating Hormone (FSH) to improve reproductive health outcomes for individuals facing infertility. Their lead candidate, IGX12, aims to increase the efficacy of existing infertility treatments, addressing the significant global need for more effective medical options.
Funding
$15.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Infertility affects millions globally, and current treatments often have limited efficacy. There is a significant need for more effective medical options to improve reproductive health outcomes for individuals facing infertility.
Solution
Igyxos Biotherapeutics is developing monoclonal antibodies designed to enhance the activity of Follicle Stimulating Hormone (FSH), a key hormone in reproduction. Their lead candidate, IGX12, aims to increase the efficacy and potency of existing infertility treatments by boosting FSH activity. This approach seeks to overcome the limitations of current infertility treatments, potentially transforming the effectiveness, efficiency, and economics of infertility treatment. The company's unique scientific approach focuses on identifying monoclonal antibodies that can significantly improve reproductive health outcomes.
Target Audience
The primary target audience includes individuals and couples facing infertility, as well as reproductive health specialists seeking more effective treatment options.
Features
- Monoclonal antibodies designed to enhance FSH activity.
- Lead candidate, IGX12, with preclinical data demonstrating potential for increasing FSH efficacy.
- Aims to improve the effectiveness, efficiency, and economics of infertility treatment.